Khora is deployed wherever scientific claims meet capital—venture funds, sell-side and buy-side research, and pharma corporate teams standardizing how they read clinical risk.
Each segment below reflects how clients structure licenses and workflows today. Figures are illustrative composites from onboarding surveys and usage telemetry and are not audited financial metrics.
Pre-IC through follow-on rounds
Analysts run standardized credibility packs for new deals, track milestone risk across the portfolio, and keep partners aligned on what evidence actually supports each thesis.
68%
of diligences closed with a shared Khora snapshot in Q4 benchmark (sample firms)
Market hours and corporate access
Coverage teams monitor PDUFA clocks, supplemental filings, and competitor trials with the same scoring rubric analysts use in deep dives. Export tiles drop straight into morning notes.
120+
live programs followed on average per healthcare desk license
Scouting and early partnering
Corporate teams benchmark inbound assets, compare trial readouts fairly across modalities, and brief leadership with defensible diligence that holds up in committee.
Threefold
faster partner review cycles reported in qualitative interviews
Life science banks, specialist consultancies, and payer strategy groups run pilots with shared evidence libraries and white-label brief templates. Reach out through Consult an Expert for segment-specific demos.
